Literature DB >> 24119624

Imaging and clinical predictors of unfavorable outcome in medically treated symptomatic intracranial atherosclerotic disease.

Mahesh Kate1, Padmavathy N Sylaja2, Chandrasekharan Kesavadas1, Bejoy Thomas1.   

Abstract

BACKGROUND: Patients with symptomatic intracranial atherosclerotic disease (sICAD) have an increased risk of stroke and vascular death. The aim of the study was to evaluate the natural history and outcome of patients with sICAD treated medically.
METHODS: The study population was first-ever transient ischemic attack (TIA) or stroke patients presenting to our institute who on vascular imaging had isolated intracranial atherosclerosis as cause of their symptoms and have a follow-up of 90 days. Unfavorable outcome was defined as occurrence of TIA, stroke, acute coronary event, and/or vascular death.
RESULTS: Fifty-three (11.8%) of the 449 ischemic stroke patients had sICAD. The risk of stroke in sICAD was 8.9%, 11.1%, 13.3%, and 15.6% in first 7 days, 30 days, 90 days, and 1 year, respectively. Five (11.1%) had cardiovascular events and accounted for 50% of mortality. The predictors of unfavorable outcome were presented as limb weakness (85.7% versus 58.8%, hazard ratio 1.5; 95% confidence interval [CI], .05-.9; P = .04), National Institutes of Health Stroke Scale (NIHSS) score 8 at admission (50% versus 5.9%, hazard ratio 8.5; 95% CI, .007-.5; P = .02), magnetic resonance imaging (MRI) with multiple diffusion-weighted imaging (DWI) lesions (65.4% versus 26.7%; 95% CI, .04-.7; P = .01), and angiography suggestive of diffuse atherosclerosis (50% versus 11.8%; 95% CI, odds ratio .02-.7; P = .009). On stepwise multiple regression, variables for unfavorable outcome were NIHSS score of 8 or more at admission (P = .001), multiple DWI lesion on MRI (P = .04), and diffuse atherosclerosis on angiography (P = .006).
CONCLUSION: The patients with sICAD have a high risk of stroke and cardiac events even on aggressive medical treatment. Clinical and imaging features can identify this high-risk group.
Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intracranial atherosclerotic disease; TIA; intracranial stenosis; predictors; stroke; treatment

Mesh:

Year:  2013        PMID: 24119624     DOI: 10.1016/j.jstrokecerebrovasdis.2013.08.002

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  5 in total

1.  A Need for Tailored Approach for Patients with Symptomatic Intracranial Atherosclerotic Stenosis.

Authors:  Mahesh P Kate; Ashfaq Shuaib
Journal:  Ann Indian Acad Neurol       Date:  2020-02-07       Impact factor: 1.383

2.  Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling.

Authors:  Nicolas Baeyens; Mary Jo Mulligan-Kehoe; Federico Corti; David D Simon; Tyler D Ross; John M Rhodes; Thomas Z Wang; Cecile O Mejean; Michael Simons; Jay Humphrey; Martin A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

3.  Multiple intracranial arterial stenosis influences the long-term prognosis of symptomatic middle cerebral artery occlusion.

Authors:  Lili Tian; Xuanye Yue; Gangming Xi; Youmeng Wang; Zongyou Li; Ying Zhou; Xiaobing Fan
Journal:  BMC Neurol       Date:  2015-04-29       Impact factor: 2.474

4.  Risk Factors, Vascular Lesion Distribution, Outcome and Recurrence of Strokes Due to Intracranial Atherosclerosis: One Year Data from Hyderabad Stroke Registry.

Authors:  Raghu Ram; Subhash Kaul; Suvarna Alladi; Jabeen S Afshan; T Surya Prabha; Abhijeet Kohat; Swetha Tandra; Jyotsna Y Rani
Journal:  Ann Indian Acad Neurol       Date:  2017 Oct-Dec       Impact factor: 1.383

5.  Comparison of Risk Factors, Treatment, and Outcome in Patients with Symptomatic Intracranial Atherosclerotic Disease in India and the United States.

Authors:  Udit Saraf; Shyam Prabhakaran; K Arun; Ahmed Babiker; Adithyan Rajendran; Chandrasekharan Kesavadas; P N Sylaja
Journal:  Ann Indian Acad Neurol       Date:  2020-06-05       Impact factor: 1.383

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.